Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G W Pledger

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Epilepsy Research. Supplement|January 1, 1988
Compliance in clinical trials: impact on design, analysis and interpretationG W Pledger
Neurology|December 1, 1989
Carbamazepine for 1st seizureG W Pledger
Journal of Biopharmaceutical Statistics|September 1, 1993
Confidence intervals versus p-values for interpretation of clinical trial results: introductionG W Pledger
Neurology|November 1, 1996
Intent-to-treatG W Pledger
Drugs|October 1, 1994
Evaluation of antiepileptic drug efficacy. A review of clinical trial designG W Pledger, D Schmidt
The New England Journal of Medicine|December 18, 1980
The FDA's critique of the anturane reinfarction trialR Temple, G W Pledger
Controlled Clinical Trials|December 1, 1991
Design of an individualized fixed-dose clinical trial to test the antiepileptic efficacy of a plasma flunarizine concentrationG W Pledger, D M Treiman
Journal of Biopharmaceutical Statistics|March 1, 1994
Dosage adjustments in response to monitored plasma concentrations: can unblinded staff adhere to objective criteria?J T Sahlroot, G W Pledger
Advances in Neurology|December 31, 1997
Reanalysis of existing trial data: what can be learnedJ T Sahlroot, G W Pledger
Epilepsy Research. Supplement|January 1, 1993
Alternative analyses for antiepileptic drug trialsG W Pledger, J T Sahlroot
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Epilepsy Research. Supplement|January 1, 1988
Compliance in clinical trials: impact on design, analysis and interpretationG W Pledger
Neurology|December 1, 1989
Carbamazepine for 1st seizureG W Pledger
Journal of Biopharmaceutical Statistics|September 1, 1993
Confidence intervals versus p-values for interpretation of clinical trial results: introductionG W Pledger
Neurology|November 1, 1996
Intent-to-treatG W Pledger
Drugs|October 1, 1994
Evaluation of antiepileptic drug efficacy. A review of clinical trial designG W Pledger, D Schmidt
The New England Journal of Medicine|December 18, 1980
The FDA's critique of the anturane reinfarction trialR Temple, G W Pledger
Controlled Clinical Trials|December 1, 1991
Design of an individualized fixed-dose clinical trial to test the antiepileptic efficacy of a plasma flunarizine concentrationG W Pledger, D M Treiman
Journal of Biopharmaceutical Statistics|March 1, 1994
Dosage adjustments in response to monitored plasma concentrations: can unblinded staff adhere to objective criteria?J T Sahlroot, G W Pledger
Advances in Neurology|December 31, 1997
Reanalysis of existing trial data: what can be learnedJ T Sahlroot, G W Pledger
Epilepsy Research. Supplement|January 1, 1993
Alternative analyses for antiepileptic drug trialsG W Pledger, J T Sahlroot
Pageof 3